Key Financial Highlights (Standalone)

Q2 FY27 Performance (₹ Crore)

  • Total Income: ₹267.64 crore vs ₹145.29 crore in Q2 FY26, representing 84.21% YoY growth
  • EBITDA: ₹42.60 crore vs ₹22.34 crore in Q2 FY26, representing 90.74% YoY growth
  • EBITDA Margin: 15.92% vs 15.37% in Q2 FY26, an improvement of 55 basis points
  • Net Profit: ₹18.83 crore vs ₹9.73 crore in Q2 FY26, representing 93.44% YoY growth
  • Net Profit Margin: 7.03% vs 6.70% in Q2 FY26, an improvement of 34 basis points

H1 FY27 Performance (₹ Crore)

  • Total Income: ₹495.88 crore vs ₹265.15 crore in H1 FY26, representing 87.02% YoY growth
  • EBITDA: ₹75.38 crore vs ₹39.33 crore in H1 FY26, representing 91.67% YoY growth
  • EBITDA Margin: 15.20% vs 14.83% in H1 FY26, an improvement of 37 basis points
  • Net Profit: ₹31.99 crore vs ₹16.50 crore in H1 FY26, representing 93.92% YoY growth
  • Net Profit Margin: 6.45% vs 6.22% in H1 FY26, an improvement of 23 basis points

Recent Business Developments

Goodman Vetcare Stake Acquisition (September 2026)

  • Acquired 26% stake in Goodman Vetcare at a valuation of ₹300 crore
  • Goodman Vetcare plans to open 8+ new stores
  • Targets ₹100 crore revenue by FY31

Furlicks Brand Acquisition (September 2026)

  • Acquired Furlicks pet wellness brand from USV and its subsidiary Wellbeing Nutrition
  • Marks company's entry into pet wellness segment
  • Furlicks produces easy-to-give oral strips covering: skin and coat health, gut health, joint care, calming products, oral care, and multivitamins
  • Plans to launch 16 new products over next 6-9 months, expanding portfolio from 6 to 22 SKUs
  • New formats to include: cold-extruded, air-dried, freeze-dried products, and functional biscuits

PAWTALKS Platform Launch (4th September 2026)

  • Launched as a pet healthcare knowledge platform
  • Features expert content on YouTube and Instagram

Management Commentary

Mr. Fredun Medhora, Managing Director, commented:

  • H1 FY27 built on strong Q1 performance with ~87% revenue growth, ~92% EBITDA growth, and ~94% net profit growth
  • Growth driven by both vintage business and new-age brands
  • Core formulations business becoming more efficient with higher-margin registrations
  • New businesses in pet care, mobility, nutrition, and dermaceuticals in high-growth phase with better margins
  • Fredun GX now present in 19 states with strong acceptance from pharmacies and distributors
  • Industry support from low medicine access in Tier 2-4 towns and strong export demand for affordable formulations
  • Consumer shift toward preventive healthcare, nutrition, and wellness
  • Pet care category rapidly evolving with pets treated as family members
  • Recent acquisitions (Furlicks, Goodman Vetcare stake) and PAWTALKS launch complement existing functional foods, diagnostics, and Wagr platform
  • Building complete pet-wellness ecosystem in India
  • Expanding capacity to build one of largest manufacturing units at single location in country
  • Widening product basket and strengthening balance sheet
  • Focus on consistent product availability, deeper market penetration, and sustainable profitable growth

Company Background

Fredun Pharmaceuticals Limited is a healthcare and pharmaceuticals company offering:

  • Antihypertensives, antidiabetic, antiretroviral drugs (ARVs), and narcotics
  • Dietary/herbal supplements, nutraceuticals, cosmeceuticals, and other healthcare products
  • Animal healthcare products
  • Primary export markets: Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries, and Latin America

FY26 Financial Reference

  • Total revenues: ₹639.12 crore
  • EBITDA: ₹94.79 crore
  • PAT: ₹33.21 crore

Disclaimer

Document contains forward-looking statements subject to risks including government actions, economic developments, technological risks, and other factors that could cause actual results to differ materially. Company undertakes no obligation to update these statements.